I think there are a lot of cogs and gears in this deal but the one factor I think people are not factoring is this 275 million was fully subscribed for 22% of the hoover company.
This means these institutions have valued the merger into hoover at 1.25 billion of which SBM is a ~38% owner. This equates to the valued portion of hoover that SBM owns as ~475 million.
Prior to this merger SBM was sitting with a market cap around 500mil at sp ~65cents, at some stages it was in the 400's when the sp was sub 60c.
This means that with this merger we are theoretically valuing the new company Phoenician metals at almost no value. Remember, Phoenician metals will have a strong balance sheet - A$85 million pro-forma cash and no debt, it will comprise of both Simberi and Atlantic assets and hold all the shares of interest in other Aus explorers/miners ~$34mil
Just something I have been thinking about with all the numbers thrown around in this deal.
- Forums
- ASX - By Stock
- SBM
- Ann: Completion of Genesis' A$275 million conditional placement
Ann: Completion of Genesis' A$275 million conditional placement, page-9
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SBM (ASX) to my watchlist
|
|||||
Last
22.5¢ |
Change
-0.010(4.26%) |
Mkt cap ! $184.0M |
Open | High | Low | Value | Volume |
23.5¢ | 24.0¢ | 22.5¢ | $364.2K | 1.569M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
31 | 818386 | 22.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.0¢ | 611309 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
30 | 831400 | 0.225 |
22 | 641397 | 0.220 |
14 | 364043 | 0.215 |
23 | 946624 | 0.210 |
12 | 1331830 | 0.205 |
Price($) | Vol. | No. |
---|---|---|
0.230 | 621602 | 19 |
0.235 | 552143 | 6 |
0.240 | 771371 | 23 |
0.245 | 575453 | 14 |
0.250 | 234944 | 14 |
Last trade - 11.02am 16/07/2024 (20 minute delay) ? |
Featured News
SBM (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online